Tamara Weiss

1.9k total citations
22 papers, 1.1k citations indexed

About

Tamara Weiss is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Tamara Weiss has authored 22 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hematology, 17 papers in Genetics and 8 papers in Molecular Biology. Recurrent topics in Tamara Weiss's work include Acute Myeloid Leukemia Research (18 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers). Tamara Weiss is often cited by papers focused on Acute Myeloid Leukemia Research (18 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers). Tamara Weiss collaborates with scholars based in Germany, United States and Italy. Tamara Weiss's co-authors include Susanne Schnittger, Torsten Haferlach, Claudia Haferlach, Wolfgang Kern, Frank Dicker, Brunangelo Falini, Alexander Kohlmann, Claudia Tschulik, Hans‐Ulrich Klein and Martin Dugas and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Tamara Weiss

22 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tamara Weiss Germany	9	945	462	456	305	117	22	1.1k
Joseph O. Moore United States	10	1.0k 1.1×	555 1.2×	368 0.8×	350 1.1×	100 0.9×	17	1.3k
Marion E. Frew United Kingdom	5	1.4k 1.5×	664 1.4×	501 1.1×	395 1.3×	111 0.9×	5	1.5k
Milena Fava Italy	8	764 0.8×	389 0.8×	352 0.8×	296 1.0×	59 0.5×	10	949
Bennett Adam Caughey United States	7	925 1.0×	386 0.8×	393 0.9×	120 0.4×	147 1.3×	17	1.0k
Kristiina Heinonen Finland	16	714 0.8×	364 0.8×	190 0.4×	369 1.2×	74 0.6×	30	918
Sandra Weißmann Germany	10	525 0.6×	396 0.9×	317 0.7×	252 0.8×	116 1.0×	28	861
Hans Beier Ommen Denmark	17	940 1.0×	544 1.2×	195 0.4×	430 1.4×	163 1.4×	44	1.1k
Sonja Schindela Germany	13	620 0.7×	368 0.8×	314 0.7×	158 0.5×	146 1.2×	25	830
J L Laï France	13	797 0.8×	372 0.8×	270 0.6×	257 0.8×	45 0.4×	23	942
Marta Pratcorona Spain	14	791 0.8×	572 1.2×	269 0.6×	214 0.7×	193 1.6×	29	1.0k

Countries citing papers authored by Tamara Weiss

Since Specialization

Citations

This map shows the geographic impact of Tamara Weiss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tamara Weiss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tamara Weiss more than expected).

Fields of papers citing papers by Tamara Weiss

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tamara Weiss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tamara Weiss. The network helps show where Tamara Weiss may publish in the future.

Co-authorship network of co-authors of Tamara Weiss

This figure shows the co-authorship network connecting the top 25 collaborators of Tamara Weiss. A scholar is included among the top collaborators of Tamara Weiss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tamara Weiss. Tamara Weiss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bacher, Ulrike, Torsten Haferlach, Susanne Schnittger, et al.. (2010). Detection of a t(4;14)(p16;q32) in two cases of lymphoma showing both the immunophenotype of chronic lymphocytic leukemia. Cancer Genetics and Cytogenetics. 200(2). 170–174. 6 indexed citations

Haferlach, Claudia, Frank Dicker, Tamara Weiss, et al.. (2010). Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters. Genes Chromosomes and Cancer. 49(9). 851–859. 40 indexed citations

Falini, Brunangelo, Tamara Weiss, Ulrike Bacher, et al.. (2010). Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). Blood. 115(18). 3776–3786. 77 indexed citations

Haferlach, Claudia, Ulrike Bacher, Tamara Weiss, et al.. (2010). Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as “AML not otherwise specified” (AML-NOS) or “AML with myelodysplasia-related changes” (AML-MRC). Blood. 116(15). 2742–2751. 69 indexed citations

Kohlmann, Alexander, Vera Großmann, Hans‐Ulrich Klein, et al.. (2010). Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia by Detecting Frequent Alterations in TET2, CBL, RAS, and RUNX1. Journal of Clinical Oncology. 28(24). 3858–3865. 220 indexed citations

Bacher, Ulrike, Susanne Schnittger, Wolfgang Kern, et al.. (2009). Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category. Annals of Hematology. 88(12). 1207–1213. 37 indexed citations

Bacher, Ulrike, Torsten Haferlach, Wolfgang Kern, et al.. (2009). The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes. Cancer. 115(19). 4524–4532. 12 indexed citations

Flach, Johanna, Sonja Schindela, Frank Dicker, et al.. (2009). Mutations of TET2 and JAK2 but Not CBL Are Detectable in a High Portion of Patients with Refractory Anemia with Ring Sideroblasts and Thrombocytosis (RARS-T).. Blood. 114(22). 1766–1766. 3 indexed citations

Schnittger, Susanne, Frank Dicker, Christiane Eder, et al.. (2009). Applicability of DHPLC for Low Sensitive Residual Disease Detection in RUNX1 and CEBPA Mutated AML.. Blood. 114(22). 3067–3067. 1 indexed citations

10.

Haferlach, Claudia, Frank Dicker, Alexander Kohlmann, et al.. (2009). AML with CBFB-MYH11 Rearrangement Is Characterized by RAS Pathway Alterations in 92% of Cases and Demonstrates a High Frequency of NF1 Deletions.. Blood. 114(22). 272–272. 2 indexed citations

11.

Schnittger, Susanne, et al.. (2009). IDH1 Mutations Are Detected in 9.3% of All AML and Are Strongly Associated with Intermediate Risk Karyotype and Unfavourable Prognosis: a Study of 999 Patients. Blood. 114(22). LBA–3. 6 indexed citations

12.

Schnittger, Susanne, Wolfgang Kern, Claudia Tschulik, et al.. (2009). Minimal residual disease levels assessed by NPM1 mutation–specific RQ-PCR provide important prognostic information in AML. Blood. 114(11). 2220–2231. 237 indexed citations

13.

Haferlach, Claudia, Torsten Haferlach, Frank Dicker, et al.. (2009). AML with Inv(3)(q21q26) or t(3;3)(q21;q26) Are Frequently Accompanied by Mutations in RUNX1 and NRAS and Show a High Incidence of NF1 Deletions: a Study On 40 Cases.. Blood. 114(22). 273–273. 1 indexed citations

14.

Cilloni, Daniela, Aline Renneville, Fabienne Hermitte, et al.. (2009). Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study. Journal of Clinical Oncology. 27(31). 5195–5201. 327 indexed citations

15.

Kohlmann, Alexander, Vera Großmann, Claudia Haferlach, et al.. (2009). Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 75% of Chronic Myelomonocytic Leukemia (CMML) by Detecting Frequent Alterations in TET2, RUNX1, CBL, and RAS.. Blood. 114(22). 417–417. 7 indexed citations

16.

Schnittger, Susanne, Ulrike Bacher, Wolfgang Kern, et al.. (2009). RQ‐PCR based WT1 expression in comparison to BCR‐ABL quantification can predict Philadelphia negative clonal evolution in patients with imatinib‐treated chronic myeloid leukaemia. British Journal of Haematology. 146(6). 665–668. 2 indexed citations

17.

Weiss, Tamara, Ulrike Bacher, Susanne Schnittger, et al.. (2009). AML with Multilineage Dysplasia (MLD) Correlates with MDS-Related Cytogenetic Abnormalities and a Prior History of MDS or MDS/MPN but Has No Independent Prognostic Relevance: A Comparison of 461 Cases Classified as “AML Not Otherwise specified” or “AML with Myelodysplasia-Related changes” as Defined by the 2008 WHO Classification.. Blood. 114(22). 823–823. 2 indexed citations

18.

Schnittger, Susanne, Frank Dicker, Tamara Weiss, et al.. (2008). RUNX1 Mutations Can Be Found in 34% of De Novo AML with Normal Karyotype or Single Chromosomal Imbalances and Are Associated with Good Prognosis but Turn to Unfavourable Outcome If Further Cytogenetic or Molecular Mutations Are Acquired. Blood. 112(11). 146–146. 2 indexed citations

19.

Thoennissen, Nils H., Norihiko Kawamata, Terra L. Lasho, et al.. (2008). Genomic Changes Associated with Leukemic Transformation of Myeloproliferative Disorders.. Blood. 112(11). 3371–3371. 1 indexed citations

20.

Schnittger, Susanne, Wolfgang Kern, Tamara Weiss, et al.. (2008). Minimal Residual Disease Assessed by NPM1 Mutation Specific RQ-PCR Is the Most Relevant Prognostic Parameter in NPM1-Mutated AML and Highly Useful to Guide Therapy. Blood. 112(11). 698–698. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact